Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$94.10 USD

94.10
1,891,045

-0.36 (-0.38%)

Updated Jul 12, 2024 03:59 PM ET

After-Market: $94.12 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls

Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.

Best Growth Stocks to Buy for February 23rd

CAH, POWL and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 23, 2024.

Best Value Stocks to Buy for February 23rd

BLDR and CAH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 23, 2024.

Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands

Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.

Best Income Stocks to Buy for February 23rd

AROC, JSAIY and CAH made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 23, 2024.

New Strong Buy Stocks for February 23rd

IRDM, JSAIY, CAH, LNTH and CENTA have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2024.

ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand

ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.

Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status

Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.

Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up

Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.

Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y

Robust revenues from Exact Sciences' (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.

Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y

Glaukos' (GKOS) fourth-quarter revenues beat estimates as well as gained year over year. Gross margin improve, while higher operating expenses lead to a wider operating loss.

Tandem Diabetes (TNDM) Posts Wider Q4 Loss, Gross Margin Down

Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.

Maharathi Basu headshot

5 Stocks Favored by Brokers Amid the Current Uncertainty

We believe that stocks like Deutsche Bank (DB), Cross Country Healthcare (CCRN), Bread Financial (BFH), American Axle (AXL) and Cardinal Health (CAH) should be on an investor's watchlist.

Here's Why You Should Retain Align Technology (ALGN) Stock Now

Investors are optimistic about Align Technology (ALGN) on continued geographic expansion.

Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?

Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.

Charles River (CRL) Gains From CRADL Amid Soft Market Scenario

Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.

Sight Sciences (SGHT) to Expand in Europe With New Launch

By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.

Avanos (AVNS) Q4 Earnings Lag Estimates, Margins Contract

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall fourth-quarter results reflect soft performances.

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

Strategic plans to drive the Knee business bode well for Zimmer Biomet (ZBH).

Globus Medical (GMED) Q4 Earnings Surpass, Margins Down

Globus Medical's (GMED) fourth-quarter 2023 performance benefits from innovative launches across its product groups.

Medtronic (MDT) Q3 Earnings Beat Estimates, 2024 View Up

Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.

GE HealthCare's (GEHC) Tie-Up to Improve Care Accessibility

GE HealthCare's (GEHC) latest alliance is likely to include investment in new technology systems, digital tools and resources, service and support across a variety of care areas.